BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:China Medical System readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies China Medical System's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07465120-1339@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:CMS-D001: Phase 2 readout est. (NCT07465120)
DESCRIPTION:CMS-D001\, phase 2\, Atopic Dermatitis.\nStudy: A Multicenter\,
  Randomized\, Double-Blind\, Placebo-Controlled\, Phase Ⅱ Clinical Study
  to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Mo
 derate to Severe Atopic Dermatitis\nEstimated primary completion: 31 Janua
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/cms-d001#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0746512
 0
URL:https://assetmemo.bio/drug/cms-d001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05179226-591@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Monoferric / Monofer (Ferric derisomaltose): Phase 3 readout est. (
 NCT05179226)
DESCRIPTION:Monoferric / Monofer (Ferric derisomaltose)\, phase 3\, Iron De
 ficiency Anemia.\nStudy: Multi-center Trial of Ferric Derisomaltose in Chi
 ldren 0 to <18 Years of Age With Iron Deficiency Anemia\nEstimated primary
  completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ferric-derisomaltose#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05179226
URL:https://assetmemo.bio/drug/ferric-derisomaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410455-1801@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Piclidenoson: Phase 2 readout est. (NCT07410455)
DESCRIPTION:Piclidenoson\, phase 2.\nStudy: An Open-label\, Phase 2 Pilot S
 tudy on the Efficacy and Safety of Piclidenoson in Patients With Lowe Synd
 rome\nEstimated primary completion: 31 August 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/piclidenoson#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07410455
URL:https://assetmemo.bio/drug/piclidenoson#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06643260-1801@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Piclidenoson: Phase 3 readout est. (NCT06643260)
DESCRIPTION:Piclidenoson\, phase 3\, Psoriasis.\nStudy: A Phase 3 Study in 
 Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and 
 Efficacy\nEstimated primary completion: December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/piclidenoson#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06643260
URL:https://assetmemo.bio/drug/piclidenoson#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06929806-591@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Monoferric / Monofer (Ferric derisomaltose): Phase 3 readout est. (
 NCT06929806)
DESCRIPTION:Monoferric / Monofer (Ferric derisomaltose)\, phase 3\, Heart F
 ailure.\nStudy: Multi-center Trial of Ferric Derisomaltose Versus no Intra
 venous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Fail
 ure\nEstimated primary completion: 1 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ferric-derisomaltose#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06929806
URL:https://assetmemo.bio/drug/ferric-derisomaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07432854-1339@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:CMS-D001: Phase 2/3 readout est. (NCT07432854)
DESCRIPTION:CMS-D001\, phase 2/3\, Psoriasis.\nStudy: A Clinical Study Eval
 uating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adu
 lt Patients With Moderate to Severe Plaque-type Psoriasis\nEstimated prima
 ry completion: 29 February 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/cms-d001#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07432854
URL:https://assetmemo.bio/drug/cms-d001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04991116-99@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ilumya (tildrakizumab): Phase 3 readout est. (NCT04991116)
DESCRIPTION:Ilumya (tildrakizumab)\, phase 3\, Psoriatic Arthritis.\nStudy:
  Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients 
 With Psoriatic Arthritis\nEstimated primary completion: December 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tildrakizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04991116
URL:https://assetmemo.bio/drug/tildrakizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
